ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ACIU AC Immune SA

3.48
-0.15 (-4.13%)
20 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
AC Immune SA NASDAQ:ACIU NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -4.13% 3.48 2.22 7.20 3.59 3.44 3.59 88,092 05:00:00

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

28/10/2022 1:02pm

Edgar (US Regulatory)


00016516252022-01-012022-09-300001651625ifrs-full:OfficeEquipmentMember2022-09-300001651625ifrs-full:ComputerEquipmentMember2022-09-300001651625ifrs-full:BuildingsMember2022-09-300001651625ifrs-full:OfficeEquipmentMember2021-12-310001651625ifrs-full:ComputerEquipmentMember2021-12-310001651625ifrs-full:BuildingsMember2021-12-310001651625ifrs-full:TopOfRangeMemberaciu:GrantFromTargetALSFoundationMember2022-07-012022-09-300001651625aciu:TauPetTracerPi2620Memberaciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember2022-07-012022-09-300001651625aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember2022-07-012022-09-300001651625aciu:GrantsMichaelJFoxFoundationMember2022-07-012022-09-300001651625ifrs-full:TopOfRangeMemberaciu:GrantFromTargetALSFoundationMember2022-01-012022-09-300001651625aciu:TauPetTracerPi2620Memberaciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember2022-01-012022-09-300001651625aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember2022-01-012022-09-300001651625aciu:GrantsMichaelJFoxFoundationMember2022-01-012022-09-300001651625ifrs-full:TopOfRangeMemberaciu:GrantFromTargetALSFoundationMember2021-07-012021-09-300001651625aciu:GrantsMichaelJFoxFoundationMember2021-07-012021-09-300001651625ifrs-full:TopOfRangeMemberaciu:GrantFromTargetALSFoundationMember2021-01-012021-09-300001651625aciu:GrantsMichaelJFoxFoundationMember2021-01-012021-09-300001651625ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2022-09-300001651625ifrs-full:GrossCarryingAmountMemberifrs-full:FixturesAndFittingsMember2022-09-300001651625ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2022-09-300001651625ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember2022-09-300001651625ifrs-full:GrossCarryingAmountMemberaciu:LaboratoryEquipmentMember2022-09-300001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2022-09-300001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:FixturesAndFittingsMember2022-09-300001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerEquipmentMember2022-09-300001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberaciu:LaboratoryEquipmentMember2022-09-300001651625ifrs-full:LeaseholdImprovementsMember2022-09-300001651625ifrs-full:FixturesAndFittingsMember2022-09-300001651625ifrs-full:ConstructionInProgressMember2022-09-300001651625ifrs-full:ComputerEquipmentMember2022-09-300001651625ifrs-full:AccumulatedDepreciationAndAmortisationMember2022-09-300001651625aciu:LaboratoryEquipmentMember2022-09-300001651625ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2021-12-310001651625ifrs-full:GrossCarryingAmountMemberifrs-full:FixturesAndFittingsMember2021-12-310001651625ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2021-12-310001651625ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember2021-12-310001651625ifrs-full:GrossCarryingAmountMemberaciu:LaboratoryEquipmentMember2021-12-310001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2021-12-310001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:FixturesAndFittingsMember2021-12-310001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerEquipmentMember2021-12-310001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberaciu:LaboratoryEquipmentMember2021-12-310001651625ifrs-full:LeaseholdImprovementsMember2021-12-310001651625ifrs-full:FixturesAndFittingsMember2021-12-310001651625ifrs-full:ConstructionInProgressMember2021-12-310001651625ifrs-full:ComputerEquipmentMember2021-12-310001651625ifrs-full:AccumulatedDepreciationAndAmortisationMember2021-12-310001651625aciu:LaboratoryEquipmentMember2021-12-310001651625ifrs-full:GrossCarryingAmountMemberaciu:InProcessResearchAndDevelopmentIPRDAssetMember2022-09-300001651625ifrs-full:GrossCarryingAmountMember2022-09-300001651625aciu:InProcessResearchAndDevelopmentIPRDAssetMember2022-09-300001651625ifrs-full:GrossCarryingAmountMemberaciu:InProcessResearchAndDevelopmentIPRDAssetMember2021-12-310001651625ifrs-full:GrossCarryingAmountMember2021-12-310001651625aciu:InProcessResearchAndDevelopmentIPRDAssetMember2021-12-310001651625ifrs-full:TreasurySharesMember2021-01-012021-09-300001651625ifrs-full:IssuedCapitalMember2022-01-012022-09-300001651625ifrs-full:NotLaterThanOneYearMember2022-09-300001651625ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2022-09-300001651625ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2022-09-300001651625ifrs-full:TopOfRangeMember2022-07-012022-09-300001651625ifrs-full:TreasurySharesMember2022-09-300001651625ifrs-full:SharePremiumMember2022-09-300001651625ifrs-full:RetainedEarningsMember2022-09-300001651625ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-09-300001651625ifrs-full:IssuedCapitalMember2022-09-300001651625ifrs-full:TreasurySharesMember2021-12-310001651625ifrs-full:SharePremiumMember2021-12-310001651625ifrs-full:RetainedEarningsMember2021-12-310001651625ifrs-full:IssuedCapitalMember2021-12-310001651625ifrs-full:TreasurySharesMember2021-09-300001651625ifrs-full:SharePremiumMember2021-09-300001651625ifrs-full:RetainedEarningsMember2021-09-300001651625ifrs-full:IssuedCapitalMember2021-09-300001651625ifrs-full:TreasurySharesMember2020-12-310001651625ifrs-full:SharePremiumMember2020-12-310001651625ifrs-full:RetainedEarningsMember2020-12-310001651625ifrs-full:IssuedCapitalMember2020-12-310001651625ifrs-full:OfficeEquipmentMember2022-01-012022-09-300001651625ifrs-full:ComputerEquipmentMember2022-01-012022-09-300001651625ifrs-full:BuildingsMember2022-01-012022-09-300001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2022-01-012022-09-300001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:FixturesAndFittingsMember2022-01-012022-09-300001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerEquipmentMember2022-01-012022-09-300001651625ifrs-full:AccumulatedDepreciationAndAmortisationMemberaciu:LaboratoryEquipmentMember2022-01-012022-09-300001651625ifrs-full:AccumulatedDepreciationAndAmortisationMember2022-01-012022-09-300001651625ifrs-full:TopOfRangeMemberaciu:GrantFromTargetALSFoundationMember2022-09-300001651625aciu:GrantsMichaelJFoxFoundationMember2022-09-300001651625ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-01-012022-09-3000016516252021-09-3000016516252020-12-310001651625ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2022-01-012022-09-300001651625ifrs-full:GrossCarryingAmountMemberifrs-full:FixturesAndFittingsMember2022-01-012022-09-300001651625ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2022-01-012022-09-300001651625ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember2022-01-012022-09-300001651625ifrs-full:GrossCarryingAmountMemberaciu:LaboratoryEquipmentMember2022-01-012022-09-300001651625ifrs-full:GrossCarryingAmountMember2022-01-012022-09-300001651625aciu:LaboratoryEquipmentMember2022-01-012022-09-300001651625aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember2022-01-012022-09-300001651625aciu:TauPetTracerPi2620Memberaciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember2022-09-300001651625ifrs-full:SharePremiumMember2022-01-012022-09-300001651625ifrs-full:RetainedEarningsMember2022-01-012022-09-300001651625ifrs-full:SharePremiumMember2021-01-012021-09-300001651625ifrs-full:RetainedEarningsMember2021-01-012021-09-300001651625ifrs-full:IssuedCapitalMember2021-01-012021-09-300001651625aciu:SkaneUniversityHospitalMemberaciu:GrantsMichaelJFoxFoundationMember2022-08-012022-08-310001651625aciu:AlphaSynucleinPetImagingDiagnosticAgentMemberaciu:GrantsMichaelJFoxFoundationMember2022-08-012022-08-3100016516252022-07-012022-09-3000016516252021-07-012021-09-3000016516252022-09-3000016516252021-12-3100016516252021-01-012021-09-30iso4217:CHFxbrli:sharesiso4217:USDxbrli:pureaciu:itemiso4217:EURiso4217:CHFiso4217:USDiso4217:CHFxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2022

Commission file number: 001-37891

AC IMMUNE SA

(Exact Name of Registrant as Specified in Its Charter)

EPFL Innovation Park

Building B

1015 Lausanne, Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F      Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes      No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes      No

This Report on Form 6-K (excluding Exhibit 99.3 herewith) is incorporated by reference into the Registrant’s registration statement on Form F-3 (File Nos. 333-227016, 333-249655 and 333-255576) and Form S-8 (File No. 333-233019).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AC IMMUNE SA

By:

/s/ Andrea Pfeifer

Name:  Andrea Pfeifer

Title:    Chief Executive Officer

By:

/s/ Christopher Roberts

Name:  Christopher Roberts

Title:    Vice President Finance and interim Chief Financial Officer

Date:     October 28, 2022

1 Year AC Immune Chart

1 Year AC Immune Chart

1 Month AC Immune Chart

1 Month AC Immune Chart

Your Recent History

Delayed Upgrade Clock